GlassScriptPhysician profile
Austin Perry
NPI 1245868835
$16,503.37
in general payments reported to CMS, 2019-2025
30 companies · $3,920 in 2025
The $3,920 reported for 2025 was more than what 97% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,829 · 2022: $2,133 · 2023: $3,661 · 2024: $4,961 · 2025: $3,920.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Consulting Fee: $1,063 · Education: $665.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,814.27 |
| Consulting Fee | $1,062.50 |
| Education | $664.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $3,199.04 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Abbvie INC. | $2,999.68 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,505.68 | 2021-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $1,089.62 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $916.75 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| Leo Pharma INC. | $745.40 | 2022-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $706.91 | 2022-2025 | |
| Genzyme Corporation | $681.25 | 2021-2025 | |
| Ucb, INC. | $637.40 | 2021-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $578.87 | 2022-2025 | Sotyktu |
| Incyte Corporation | $569.25 | 2021-2025 | Opzelura, Opzelura |
| Dermavant Sciences, INC. | $567.60 | 2022-2024 | Vtama |
| Pfizer INC. | $521.20 | 2021-2025 | |
| Amgen INC. | $415.86 | 2021-2024 | Otezla |
| Arcutis Biotherapeutics, INC. | $355.29 | 2023-2025 | Zoryve |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $277.92 | 2021-2025 | Jublia, Siliq, Cabtreo |
| Galderma Laboratories, L.P. | $144.79 | 2021-2025 | Nemluvio |
| Fresenius Kabi USA, LLC | $106.08 | 2023 | Idacio |
| Sanofi-Aventis U.S. LLC | $99.99 | 2023 | |
| Vyne Pharmaceuticals INC. | $74.46 | 2021 | |
| Genentech USA, INC. | $71.42 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $49.46 | 2023-2025 | Valchlor |
| Biofrontera INC. | $42.51 | 2021-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Organon LLC | $28.64 | 2025 | Vtama |
| Botanix Sb INC | $22.68 | 2025 | Sofdra |
| Paratek Pharmaceuticals, INC. | $22.60 | 2022 | |
| Sandoz INC. | $21.59 | 2023 | Hyrimoz |
| Merck Sharp & Dohme LLC | $20.68 | 2022 | |
| Advanced Oxygen Therapy INC. | $16.03 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $14.72 | 2024 | Simlandi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Austin Perry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.